EMR › analyze
EMR · Analyze
Date: 2026-03-21 Price: ~$128 | 52wk: $104–$165 | Market Cap: ~$72.7B Sector: Electrical Infrastructure / Industrial Automation Dividend King: 69 consecutive years of increases
Phase 1 Summary (Fundamentals + Sentiment + Qualitative Moat)
Fundamentals Analyst — Financial Health
| Metric | Value | Assessment |
|---|---|---|
| Revenue (FY2025) | $18.0B | Guided 5% organic CAGR through 2028 |
| Gross Margin | 52.8% (up from 45.7% FY2022) | +710bps in 3yr — software transformation visible |
| FCF (cont. ops) | $3.25B | Strong; 3yr CAGR ~23% |
| FCF/Share | $5.73 | P/FCF ~22x |
| Trailing EPS | $4.04 | Depressed by transformation costs/impairments |
| Forward EPS (FY2026) | ~$7.15 (consensus) | Fwd P/E ~17.9x |
| Debt | $13.8B total ($4.8B short-term) | Spiked from $8.4B for AspenTech privatization |
| Net Debt | $11.6B | Net debt/FCF ~3.6x |
| Debt-to-Assets | 32.8% | Elevated but not alarming for industrial |
| Shares Outstanding | ~568M | Stable |
| Dividend | $2.22/share (1.73% yield) | ~39% FCF payout, ~5% recent growth |
| ROIC (reported) | 6.7–9.9% | Below WACC (~11.9%) — distorted by goodwill |
2028 Management Targets: $21B revenue, 30% adj EBITA margin, $8.00 adj EPS, $12B cumulative FCF (FY2025–2028)
Sentiment Analyst — Key Findings
- CEO Lal Karsanbhai executing the most aggressive transformation in EMR's history — divesting legacy businesses, acquiring AspenTech and NI to pivot toward industrial software/automation
- $15B+ in acquisitions financed with significant debt; market is watching execution closely
- 69-year Dividend King status provides institutional investor confidence
- China/Supcon competitive threat in emerging markets is real but manageable — EMR's installed base in developed markets is deeply entrenched
- Analyst consensus is cautiously optimistic; price targets cluster $135–$155
Qualitative Moat — Key Findings
- DCS switching costs: Among strongest in industrial tech — 15–25yr replacement cycles, safety-critical applications
- AspenTech: 80%+ market share in downstream refining simulation — deeply embedded process models
- Sensor-to-software integration: Compelling strategy but unproven at scale
- Risks: $15B+ acquisition spending (execution risk), Chinese competition in emerging markets
- Assessment: STRONG moat with execution risk on transformation
Phase 2A: Moat Analyst — Quantitative Completion
ROIC/Margin Trend Analysis
The headline ROIC of 6.7–9.9% looks damning — it's below the estimated WACC of ~11.9%. But this number is deeply misleading and must be unpacked.
Why reported ROIC understates economic returns:
EMR's balance sheet carries ~$27.7B in acquisition goodwill and intangibles — roughly 66% of total assets ($42B). This is the accounting residue of paying fair (or premium) prices for AspenTech, NI, and earlier acquisitions. ROIC calculated on this inflated capital base will always look poor for serial acquirers.
| ROIC Calculation | Capital Base | NOPAT (est.) | ROIC |
|---|---|---|---|
| Reported (total capital) | ~$34B | $2.3–3.4B | 6.7–9.9% |
| Adjusted (tangible capital only) | ~$6.3B | $2.3–3.4B | 37–54% |
| Adjusted (tangible + 50% goodwill) | ~$20.2B | $2.3–3.4B | 11.4–16.8% |
The tangible capital ROIC is exceptionally high, confirming that EMR's core operations — the sensors, the DCS systems, the measurement instruments — generate outstanding returns. The question is whether the acquired businesses generate adequate incremental returns on the price paid.
Gross margin trajectory tells the real story:
| Year | Gross Margin | Interpretation |
|---|---|---|
| FY2022 | 45.7% | Pre-transformation baseline |
| FY2023 | 48.1% | AspenTech consolidation begins |
| FY2024 | 50.4% | Software mix increasing |
| FY2025 | 52.8% | +710bps — transformation clearly working |
A 710bps gross margin expansion in three years is remarkable for a $18B industrial company. This confirms the software/automation mix shift is real — software businesses carry 70–80% gross margins vs. 35–45% for traditional industrial hardware. If the trajectory holds, EMR could reach 55%+ gross margins by 2028, placing it firmly in the "industrial software" category rather than "industrial conglomerate."
NI Acquisition Returns Assessment
National Instruments was acquired for $8.2B in October 2023. Evaluating early returns:
- NI pre-acquisition revenue: ~$1.7B with ~20% operating margins
- Strategic rationale: Test & measurement hardware + software completes the "sensor-to-software" loop — design, test, measure, control, optimize
- Integration status: Still in early innings (18 months in). EMR is cross-selling NI's test equipment into its existing process automation customer base
- Early signal: The gross margin expansion from 50.4% to 52.8% in FY2025 includes NI's contribution — positive but not conclusive
- Concern: $8.2B for a $1.7B revenue business at ~20% margins implies EMR needs to grow NI revenue to $2.5B+ and expand margins to 25%+ to justify the price at a 10% hurdle rate. That's achievable over 5 years but not guaranteed.
Verdict on NI: Too early to declare victory or failure. The strategic logic is sound — NI fills a genuine gap in EMR's portfolio. But the price was full, and EMR needs 3–5 years to prove the cross-selling thesis. This is a "trust but verify" situation.
Evergreen Rating: 7.5/10
Can this moat persist 10+ years?
The core moat — DCS switching costs, AspenTech's process simulation monopoly, EMR's installed base in safety-critical applications — is exceptionally durable. These aren't businesses that get disrupted by a startup in a garage. Replacing a DCS in a refinery is a multi-year, $50M+ project with genuine safety implications.
The deduction from a potential 9/10 comes from: - Execution risk on transformation (-1.0): CEO Karsanbhai has been in the role only 5 years and is attempting the most aggressive portfolio reshaping in EMR's 69-year history. The strategy is sound, but the integration of $15B+ in acquisitions is not yet proven at scale. - China/emerging market pressure (-0.5): Supcon and other Chinese competitors are gaining share in basic automation. This won't threaten EMR's developed-market strongholds, but it caps upside in the fastest-growing geographies.
What would kill this moat? 1. A fundamental shift away from DCS architectures toward open, modular control systems (possible in 10–15 years but unlikely in 10) 2. AspenTech failing to maintain its simulation monopoly (low probability — the switching costs are enormous) 3. A botched integration that causes talent flight and customer defection (the real near-term risk)
Moat Defense Evaluation
Is management investing wisely to widen the moat? Yes, with caveats.
| Investment | Cost | Strategic Logic | Grade |
|---|---|---|---|
| AspenTech privatization | ~$7.5B (incremental) | Full control of best-in-class process simulation software. Eliminates minority interest friction. | A- |
| NI acquisition | $8.2B | Completes sensor-to-software loop. Opens test/measurement market. | B+ |
| Divestitures (Climate, InSinkErator) | Net proceeds | Exited commoditized, low-moat businesses. Capital recycled into software. | A |
| Organic R&D | ~$1.2B/yr | Investing in cloud migration, edge computing, AI-driven optimization | B+ |
The strategy of divesting low-moat hardware businesses and reinvesting into high-switching-cost software is exactly right. The concern is pace and price — EMR paid full prices for both AspenTech and NI, leaving less margin for error.
Moat Analyst Final Assessment: STRONG moat (7.5/10 Evergreen). The competitive advantages are structural and durable. The transformation strategy is directionally correct. The key risk is execution — can management integrate $15B+ in acquisitions while maintaining the culture and customer relationships that make EMR's moat work?
Phase 2B: Valuation Analyst
Model 1: Graham's Intrinsic Value
Formula: √(22.5 × EPS × BVPS)
| Input | Value | Notes |
|---|---|---|
| EPS (trailing) | $4.04 | Depressed by transformation costs |
| EPS (forward) | $7.15 | Consensus FY2026 |
| BVPS (est.) | ~$17.50 | Equity depressed by goodwill-heavy balance sheet |
Using trailing EPS: √(22.5 × 4.04 × 17.50) = √($1,590.75) = $39.88 Using forward EPS: √(22.5 × 7.15 × 17.50) = √($2,815.31) = $53.06
Interpretation: Graham's number is essentially useless here. EMR's trailing EPS is distorted by one-time transformation costs, and BVPS is meaningless for a company with $27.7B in goodwill (the book value of equity is artificially depressed relative to the earning power of the business). Graham's model was designed for stable value stocks with clean balance sheets — EMR in transformation is neither. Discard this model for EMR.
Model 2: Bogle's Expected Return
Formula: Dividend Yield + Earnings Growth ± P/E Change
| Component | Estimate | Notes |
|---|---|---|
| Current dividend yield | 1.73% | Solid starting point |
| Earnings growth (5yr) | +10% CAGR | Mgmt targets $8.00 adj EPS by 2028 (~12% CAGR); apply skepticism haircut |
| P/E change (annual) | 0% to +1.5% | Currently 17.9x fwd — if transformation succeeds, multiple could expand to 20–22x |
Conservative (no multiple expansion): 1.73% + 10% = ~11.7% annual return Moderate (modest expansion to 20x): 1.73% + 10% + 1.1% = ~12.8% annual return Optimistic (expansion to 22x): 1.73% + 10% + 2.1% = ~13.8% annual return
Interpretation: Bogle's model is more useful here. Even the conservative case suggests a double-digit annual return if management hits its earnings targets. The key variable is earnings growth — if the 10% CAGR target proves optimistic and actual delivery is 7%, the return compresses to ~8.7%, which is mediocre. The model confirms that EMR is reasonably priced if you believe the transformation story.
Model 3: Dividend Discount Model (DDM)
EMR is a 69-year Dividend King — DDM is highly appropriate here.
| Scenario | Dividend Growth | Discount Rate | Fair Value |
|---|---|---|---|
| Conservative | 5% | 10% | $2.22 × 1.05 / (0.10 - 0.05) = $46.62 |
| Base | 6% | 9.5% | $2.22 × 1.06 / (0.095 - 0.06) = $67.26 |
| Optimistic | 7% | 9% | $2.22 × 1.07 / (0.09 - 0.07) = $118.77 |
| Aggressive | 7.5% | 9% | $2.22 × 1.075 / (0.09 - 0.075) = $159.10 |
Interpretation: The single-stage DDM is highly sensitive to the growth-discount rate spread. The conservative and base cases suggest EMR is overvalued on dividend income alone. The optimistic case approaches current price, and the aggressive case exceeds it. This tells us that at $128, the market is pricing in approximately 7–7.5% long-term dividend growth with a ~9% required return. Given EMR's ~5% recent dividend growth rate and management's target of accelerating earnings (which would support faster dividend growth), this is plausible but requires the transformation to succeed. DDM says EMR is fairly valued if dividend growth accelerates to 7%+; overvalued if it stays at 5%.
Model 4: Dividend Yield Theory (DYT)
| Period | Average Yield | Current Yield | Signal |
|---|---|---|---|
| 5-year avg | ~2.1–2.3% (est.) | 1.73% | Overvalued — current yield below average |
| 10-year avg | ~2.3–2.6% (est.) | 1.73% | Overvalued — current yield well below average |
| Pre-transformation avg (2015–2020) | ~2.6–3.0% | 1.73% | Overvalued on historical basis |
Interpretation: DYT says EMR is trading above its historical yield-implied fair value. But there's an important caveat: EMR pre-transformation was a different company — a diversified industrial conglomerate. The transformed EMR (higher margins, software mix, faster growth) arguably deserves a lower dividend yield (higher price relative to dividend) than the old EMR. If we compare to industrial automation peers:
| Peer | Dividend Yield | Fwd P/E |
|---|---|---|
| HON (Honeywell) | ~2.1% | ~19x |
| ROK (Rockwell) | ~1.7% | ~24x |
| Siemens | ~2.5% | ~18x |
| EMR (current) | 1.73% | ~17.9x |
EMR's yield is comparable to Rockwell (a pure industrial automation play) but EMR trades at a significantly lower P/E. This suggests the market hasn't fully re-rated EMR as a software-adjacent industrial. DYT is inconclusive — the historical average is no longer the right benchmark for a transforming company.
Model 5: FCF-Based Valuation
This is the most relevant model for EMR given its transformation.
| Scenario | FCF Estimate | Target FCF Yield | Fair Value |
|---|---|---|---|
| Bear (execution stumbles) | $3.0B FCF, flat growth | 5.5% yield (industrial) | $3.0B / 0.055 / 568M = $95.70/share |
| Base (hits 2028 targets) | $4.0B FCF by 2028 (discounted) | 4.5% yield (premium industrial) | $4.0B / 0.045 / 568M = $156.50/share |
| Bull (beats targets, re-rated) | $4.5B FCF by 2028 (discounted) | 3.5% yield (software-adjacent) | $4.5B / 0.035 / 568M = $226.30/share |
Discounting to present value (10% rate, ~2.5 years to FY2028):
| Scenario | FV at 2028 | PV Today | Upside/Downside |
|---|---|---|---|
| Bear | $95.70 | ~$79 | -38% |
| Base | $156.50 | ~$129 | +1% |
| Bull | $226.30 | ~$187 | +46% |
Interpretation: The FCF-based model suggests EMR is fairly valued in the base case at ~$128. The asymmetry is moderately favorable — the bull case upside (+46%) exceeds the bear case downside (-38%), but the bear case is still painful. The key question is what FCF yield the market should demand: 4.5% (premium industrial) is the base case, but if EMR achieves 40%+ software revenue mix, a 3.5% yield (software-adjacent) is defensible.
Valuation Analyst Summary
| Model | Fair Value Range | Weight | Notes |
|---|---|---|---|
| Graham | $40–53 | 0% | Inapplicable — distorted inputs |
| Bogle | 11.7–13.8% annual return | 20% | Useful directional signal; depends on earnings growth |
| DDM | $67–159 | 20% | Wide range; sensitive to growth assumptions |
| DYT | Inconclusive | 10% | Historical benchmark no longer valid for transformed EMR |
| FCF-based | $95–226 (PV: $79–187) | 50% | Most relevant model for a transforming company |
Weighted Fair Value Range:
| Case | Fair Value | Key Assumption |
|---|---|---|
| Bear | $90–100 | Transformation stumbles, organic growth 3%, industrial multiple |
| Base | $125–140 | Hits most 2028 targets, moderate re-rating |
| Bull | $170–190 | Exceeds targets, re-rated as software-adjacent industrial |
At $128, EMR is trading at approximately base-case fair value. It is not cheap, but it is not expensive — the market is pricing in moderate transformation success. The opportunity would be significantly more compelling at $105–115 (a pullback to the low end of the 52-week range), where you'd get a meaningful margin of safety.
Phase 3: Tension Resolution
Tension 1: Reported ROIC Below WACC
Resolution: The goodwill distortion is real and material. Reported ROIC of 6.7–9.9% vs. WACC of ~11.9% would normally be a dealbreaker. But EMR's $27.7B in goodwill/intangibles represents 66% of total assets. On tangible capital alone, ROIC is 37–54% — exceptional. The relevant question is not "is reported ROIC above WACC?" but "are the acquired businesses generating adequate incremental returns on the purchase price?"
For AspenTech: Likely yes — 80%+ market share with massive switching costs in process simulation commands premium economics. The privatization removes minority interest friction and allows full margin optimization.
For NI: Too early to tell. The $8.2B price requires meaningful revenue synergies to justify.
Weight: 60% in favor of adequate returns. The goodwill distortion is well-understood by institutional investors. Monitor NI integration closely through FY2027.
Tension 2: Debt Spike ($13.8B, $4.8B Short-Term)
Resolution: Manageable but warrants monitoring. With $3.25B annual FCF and improving, EMR can service this debt. The $4.8B in short-term maturities is the near-term concern — refinancing in the current rate environment will be more expensive than original issuance. However:
- EMR is investment-grade rated (A2/A by Moody's/S&P historically)
- FCF trajectory is upward ($12B cumulative target through 2028)
- Management has explicitly stated deleveraging is a capital allocation priority
- Net debt/EBITDA is ~2.5x, within acceptable range for industrial companies
Weight: 70% manageable. This is a timing risk, not a solvency risk. The debt will come down as FCF grows and transformation spending normalizes.
Tension 3: 69-Year Track Record vs. 5-Year CEO
Resolution: The track record and the transformation are both real. Karsanbhai inherited a company that needed to evolve. The divestitures (Climate Technologies, InSinkErator) were the right moves — exiting commoditized businesses to fund higher-moat acquisitions. The 69-year dividend streak provides a cultural guardrail: EMR's board and management know that cutting the dividend would be catastrophic for their investor base.
The risk is not that Karsanbhai is reckless — it's that the transformation is complex. Integrating AspenTech, NI, and the remaining EMR portfolio into a coherent "sensor-to-software" platform while maintaining operating performance is genuinely difficult.
Weight: 65% in favor of successful transformation. The strategic direction is correct. Execution is the variable, and we won't have full clarity until FY2027–2028.
Tension 4: Industrial vs. Software Valuation Multiple
Resolution: EMR deserves a premium industrial multiple, not a full software multiple. At 52.8% gross margins and rising, EMR is migrating away from traditional industrial peers (HON at ~37%, GE Vernova at ~30%) toward industrial software territory. But it's not there yet — hardware still represents 50%+ of revenue, and the installed-base services model, while high-margin, is not the same as pure SaaS recurring revenue.
| Classification | Fair P/E Range | EMR Qualification |
|---|---|---|
| Traditional industrial | 15–18x | No longer — margins too high, software mix too large |
| Premium industrial | 18–22x | Current — 52.8% GM, growing software mix, but still hardware-heavy |
| Software-adjacent industrial (target) | 22–27x | Future — if 40%+ software revenue achieved by 2028 |
Weight: EMR deserves 18–22x forward earnings today, expanding toward 22–25x if the 2028 software mix targets are achieved. At 17.9x forward, EMR is trading at the low end of its appropriate range.
Tension 5: China/Emerging Market Risk
Resolution: Real but bounded. EMR's ~30–35% international revenue includes meaningful China exposure. Supcon is a credible competitor in basic process automation. However:
- EMR's highest-value products (DCS, safety systems, advanced analytics) are not easily replicated
- The safety-critical certification barriers in developed markets protect the core profit pool
- China risk is more about growth limitation than installed-base erosion
Weight: 15% risk to thesis. This is a growth ceiling risk, not an existential threat. Monitor but don't overweight.
Phase 4: Final Verdict
Conviction Score: 7/10
Justification: EMR is a structurally strong business with durable competitive advantages undergoing a well-conceived transformation. The moat is real, the margins are improving, and the strategic direction is correct. However, the stock is fairly valued at $128 — not cheap enough to compensate for the execution risk inherent in integrating $15B+ in acquisitions. The conviction score reflects strong fundamentals and moat offset by fair-to-full pricing and transformation uncertainty.
For context: an 8+ would require either (a) the same quality at a cheaper price ($105–115), or (b) clear evidence that the 2028 targets are being achieved ahead of schedule.
Scenario Analysis
| Scenario | Probability | Fair Value | Annual Return (5yr) | Key Driver |
|---|---|---|---|---|
| Bull | 25% | $170–190 | 13–15% | Exceeds 2028 targets, re-rated to 22–25x, dividend growth accelerates to 8%+ |
| Base | 50% | $125–140 | 8–10% | Hits most 2028 targets, gradual re-rating, 6% dividend growth |
| Bear | 25% | $90–100 | -2% to +2% | Integration stumbles, organic growth disappoints, multiple contracts to 15–16x |
Expected return (probability-weighted): ~9.5% annually. This is adequate but not compelling for a stock carrying meaningful transformation risk.
Key Risks (Ranked)
- Integration execution (HIGH): $15B+ in acquisitions need to deliver revenue synergies and margin expansion to justify the prices paid. NI integration is the most uncertain.
- Debt load / refinancing (MEDIUM-HIGH): $4.8B in short-term maturities need refinancing. Rising rates increase cost of capital.
- 2028 target miss (MEDIUM): If organic growth comes in at 3% instead of 5%, or operating margins plateau below 30%, the transformation narrative breaks.
- China competitive pressure (MEDIUM-LOW): Supcon and other Chinese competitors eroding share in emerging markets, capping growth.
- Key person risk (LOW-MEDIUM): CEO Karsanbhai is the architect of this transformation. Departure would create significant uncertainty.
Portfolio Fit
| Factor | Assessment |
|---|---|
| Current exposure | Zero industrial automation or electrical infrastructure. EMR would be a new sector. |
| Adjacent holdings | SMR and LEU (nuclear/energy) — EMR's process automation serves nuclear/energy end markets, providing thematic overlap without duplication |
| Growth + Income balance | Excellent fit — 1.73% yield growing at 5–7%, plus 10%+ earnings growth. Fills the "growing dividend" sleeve |
| Diversification benefit | High — industrial automation is uncorrelated with current portfolio's tech/nuclear concentration |
| Position sizing | Start small (1.5–2.5%) given transformation uncertainty. Add on dips or after 2028 target confirmation |
Recommendation: WATCH — Buy on Pullback
Target entry: $105–118
At $128, EMR is fairly valued. The risk/reward is adequate but not compelling. The opportunity to build a position at a margin of safety will likely come from:
- Broader market correction (EMR fell to $104 in the past 12 months)
- A weak quarterly report during the transformation (temporary noise creating opportunity)
- Refinancing anxiety around the $4.8B short-term debt maturities
Action plan: 1. Set price alert at $118 (starter position territory — ~8% discount to base fair value) 2. Set price alert at $108 (aggressive accumulation — strong margin of safety) 3. Re-evaluate after FY2026 Q2 earnings for early integration signals from NI 4. Compare to ETN and HUBB if the entire electrical infrastructure sector pulls back — EMR is the best value but ETN may have the widest moat
Dividend Grower Overlay
| Metric | Value | Assessment |
|---|---|---|
| Current yield | 1.73% | Below portfolio's ideal 2%+ entry, but acceptable for growth |
| Dividend growth (recent) | ~5%/yr | Solid; potential to accelerate to 7%+ as FCF grows |
| Dividend CAGR target | 6–8% (next 5yr) | If $8.00 EPS by 2028, payout ratio drops to ~28%, enabling acceleration |
| FCF payout ratio | ~39% | Very safe — ample room for dividend growth |
| Years to 3% yield-on-cost | ~11 years at 5% growth, ~8 years at 7% growth | Long runway, but that's the nature of Dividend Kings |
| Streak | 69 years | Virtually no risk of a cut — institutional pride and investor base demand it |
| Yield-on-cost at $110 entry | 2.02% → 3.0% in ~7yr at 6% growth | Materially better economics at target entry |
Income trajectory at $110 entry (1,000 shares = $110,000):
| Year | Annual Dividend/Share | Annual Income | Yield-on-Cost |
|---|---|---|---|
| Year 1 | $2.22 | $2,220 | 2.02% |
| Year 3 | $2.50 | $2,496 | 2.27% |
| Year 5 | $2.80 | $2,804 | 2.55% |
| Year 10 | $3.75 | $3,753 | 3.41% |
| Year 15 | $5.03 | $5,025 | 4.57% |
This is a classic Dividend King trajectory — unspectacular starting yield that compounds into a meaningful income stream over 10–15 years. The safety of the dividend (39% FCF payout, 69-year streak) compensates for the modest starting yield.
Manager's Synthesis
Emerson Electric is a genuinely interesting investment at the right price. The moat is real — DCS switching costs and AspenTech's simulation monopoly are structural advantages that won't erode in a decade. The transformation strategy is directionally correct, and the gross margin expansion from 45.7% to 52.8% provides tangible evidence it's working.
The problem is price. At $128, you're paying base-case fair value for a company with meaningful execution risk. The 17.9x forward P/E is cheap relative to where EMR could trade if the transformation succeeds (22–25x), but it's fair for where the company is today — mid-transformation with $13.8B in debt and unproven NI integration.
The patient play is to watch for a pullback to $105–118, where you'd get a genuine margin of safety. EMR traded at $104 within the past year, so this isn't a pipe dream. When the entry presents itself, this is a 2–3% portfolio position — meaningful enough to benefit from the transformation, small enough to absorb the execution risk.
One key differentiator: EMR at $110 would be a better risk/reward than ETN at $300, despite ETN having the wider moat. EMR is earlier in its re-rating cycle, with more margin expansion ahead and a lower starting valuation. If you can only own one electrical infrastructure name, EMR at the right price is the value play; ETN is the quality play.
Bottom line: Strong company, fair price, watch for a better entry. Conviction 7/10.